THROMBOLYSIS ENHANCING ACTIVITY OF A LOW MOLECULAR WEIGHT DERMATAN SULFATE (DESMIN 370) IN EXPERIMENTAL PULMONARY EMBOLISM IN RATS

Background: Patients admitted to hospital for surgery or acute medical illnesses have a high risk for venous thromboembolism (VTE). Today’s widespread use of low molecular weight heparins (LMWH) for VTE prophylaxis is supposed to have reduced VTE rates substantially. However, data concerning the overall effectiveness of LMWH prophylaxis is sparse. Patients and methods: We prospectively studied all patients with symptomatic and objectively confirmed VTE seen in our hospital over a three year period. Event rates in different wards were analysed and compared. VTE prophylaxis with Enoxaparin was given to all patients at risk during their hospital stay. Results: A total of 50 464 inpatients were treated during the study period. 461 examinations were carried out for symptoms suggestive of VTE and yielded 89 positive results in 85 patients. Seventy eight patients were found to have deep vein thrombosis, 7 had pulmonary embolism, and 4 had both deep venous thrombosis and pulmonary embolism. The overall in hospital VTE event rate was 0.17%. The rate decreased during the study period from 0.22 in year one to 0,16 in year two and 0.13 % in year three. It ranged highest in neurologic and trauma patients (0.32%) and lowest (0.08%) in gynecology-obstetrics. Conclusions: With a simple and strictly applied regimen of prophylaxis with LMWH the overall rate of symptomatic VTE was very low in our hospitalized patients. Beside LMWH prophylaxis, shortening hospital stays and substantial improvements in surgical and anasthesia techniques achieved during the last decades probably play an essential role in decreasing VTE rates.

Download Full-text

Experimental pulmonary embolism: Effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin

Journal of Vascular Surgery ◽

10.1016/j.jvs.2005.12.010 ◽

2006 ◽

Vol 43 (4) ◽

pp. 800-808 ◽

Cited By ~ 12

Author(s):

John E. Rectenwald ◽

K. Barry Deatrick ◽

Pasu Sukheepod ◽

Erin M. Lynch ◽

Andrea J. Moore ◽

...

Keyword(s):

Molecular Weight ◽

Pulmonary Embolism ◽

Pulmonary Artery ◽

Low Molecular Weight Heparin ◽

Low Molecular Weight ◽

Artery Injury

Download Full-text

Comparison of a once Daily with a twice Daily Subcutaneous Low Molecular Weight Heparin Regimen in the Treatment of Deep Vein Thrombosis

Thrombosis and Haemostasis ◽

10.1055/s-0037-1615089 ◽

1998 ◽

Vol 79 (05) ◽

pp. 897-901 ◽

Cited By ~ 52

Author(s):

Bernard A. Charbonnier ◽

Jean-Noël Fiessinger ◽

J. D. Banga ◽

Ernst Wenzel ◽

Pascal d’Azemar ◽

...

Keyword(s):

Molecular Weight ◽

Pulmonary Embolism ◽

Deep Vein Thrombosis ◽

Low Molecular Weight Heparin ◽

Low Molecular Weight ◽

Daily Regimen ◽

Once Daily ◽

Daily Group ◽

Vein Thrombosis ◽

Deep Vein

SummaryBackground: Clinical trials have been performed to compare with standard heparin a once or a twice daily regimen of low-molecular-weight heparin but no direct comparison has been done between these two low-molecular-weight heparin regimens in terms of efficacy and safety with a long-term clinical evaluation.Methods: Patients with proximal deep vein thrombosis, confirmed by venography were randomly assigned to either nadroparin (10,250 AXa IU/ml) twice daily or nadroparin (20,500 AXa IU/ml) once daily for at least 5 days. Regimens were adjusted to bodyweight. Oral anticoagulants were started on day 1 or 2 and continued for 3 months. Patients were followed up for 3 months. The composite outcome of venous thromboembolism and death possibly related to pulmonary embolism was the primary measure of efficacy. Major bleeding was the principal measure of safety. The study was designed to show equivalence between the two regimens.Results: Recurrent thromboembolic events or death possibly related to pulmonary embolism were reported in 13 patients in the once daily group (4.1%) and in 24 patients of the twice daily group (7.2%): (absolute difference 3.1% in favor of the once daily regimen; 95% confidence interval -6.6%, +0.5%). Major bleeding episodes during nadroparin treatment occurred in 4 (1.3%) and 4 patients (1.2%) in the once and twice daily groups, respectively.Conclusions: A nadroparin regimen of one injection per day is at least as effective and safe as the same total daily dose divided over two injections for the treatment of acute deep vein thrombosis.

Download Full-text

Interaction between Histidine-Rich Glycoprotein and Platelet Factor 4 with Dermatan Sulfate and Low-Molecular-Weight Dermatan Sulfate

Angiology ◽

10.1177/000331979204300107 ◽

1992 ◽

Vol 43 (1) ◽

pp. 59-62 ◽

Cited By ~ 19

Author(s):

Giuseppe Cella ◽

Giuseppe Boeri ◽

Graziella Saggiorato ◽

Rossella Paolini ◽

Guido Luzzatto ◽

...

Keyword(s):

Molecular Weight ◽

Dermatan Sulfate ◽

Platelet Factor 4 ◽

Low Molecular Weight ◽

Platelet Factor

Download Full-text

Low-molecular Weight Heparin for Treatment of Pulmonary Embolism in a Pregnant Woman

Thrombosis and Haemostasis ◽

10.1055/s-0037-1614393 ◽

1999 ◽

Vol 82 (10) ◽

pp. 1361-1362 ◽

Cited By ~ 3

Author(s):

Robert Stiller ◽

Gina Dunston-Boone ◽

John Whetham ◽

Steven Laifer

Keyword(s):

Molecular Weight ◽

Pulmonary Embolism ◽

Pregnant Woman ◽

Low Molecular Weight Heparin ◽

Low Molecular Weight

Download Full-text

INFLUENCE OF THE SULFATION PATTERN ON CERTAIN BIOLOGICAL PROPERTIES OF GALACTOSAMINOGLYCANS

10.1055/s-0038-1643251 ◽

1987 ◽

Author(s):

B Casu ◽

L Marchese ◽

A Naggi ◽

G Torri ◽

J Fareed ◽

...

Keyword(s):

Molecular Weight ◽

Dermatan Sulfate ◽

Anticoagulant Activity ◽

Chlorosulfonic Acid ◽

Biological Properties ◽

Sulfated Polysaccharides ◽

Low Molecular Weight ◽

Antithrombotic Activity

In order to investigate the influence of charge distribution and chain length on the biological properties of sulfated polysaccharides, additional sulfate groups were introduced into the galactosaminoglycans, chondriotin sulfate and dermatan sulfate. Using a flexible method (with sulfuric acid and chlorosulfonic acid) for concurrent sulfation and controlled depolymerization, numerous products were obtained and characterized by chemical, enzymatic and nuclear magnetic resonance spectroscopic methods. The biologic actions of these products were profiled in both in vitro and in vivo assays for antithrombotic activity. Despite a weaker in vitro anticoagulant activity, low molecular weight over sulfated galactosaminoglycans produced significant dose-dependent antithrombotic actions in animal models which were similar to the actions observed with oversulfated low molecular weight heparins. These results suggest that a significant antithrombotic activity can be elicited through non-specific interactions of polysulfates with cellular and plasma components, and that clusters of sulfate groups such as the 4-6 disulfate group on D-galactosaminoglycan residues may be important for these interactions. Furthermore, these results, also suggest that supersulfation of glycosaminogly-cans results in products with biologic activity distinct from the native material.

Download Full-text

Enoxaparin-Induced Liver Injury

Case Reports in Gastroenterology ◽

10.1159/000508471 ◽

2020 ◽

Vol 14 (2) ◽

pp. 315-319 ◽

Cited By ~ 2

Author(s):

Shehriyar Mehershahi ◽

Nikhitha Mantri ◽

Aneesh Kumar ◽

Shaikh Danial ◽

Patel Harish

Keyword(s):

Molecular Weight ◽

Pulmonary Embolism ◽

Liver Injury ◽

Low Molecular Weight Heparin ◽

Liver Enzymes ◽

Low Molecular Weight ◽

Dramatic Improvement ◽

Hepatocellular Injury

Enoxaparin, a form of low-molecular-weight heparin, can cause a rare, underreported, and often reversible form of hepatocellular injury. This report describes a case of enoxaparin-induced hepatotoxicity in a 61-year-old male diagnosed with pulmonary embolism. Elevations of liver enzymes were noted within 1 week of starting the drug, followed by a dramatic improvement upon its discontinuation, with subsequent normalization in the following days.

Download Full-text